Cell and gene therapy

#CAR-T #Cell and gene therapy #Collaboration #Drug development #Drug discovery

Sitting down with… Julian Cole, Cell & Gene Collective 

The Cell & Gene Collective publicly launched in May 2021. Lu Rahman caught up with Julian Cole, Country Medical Director of Gilead Sciences for the UK and Ireland to find out more about this cross-industry alliance between Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis. Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biologics #Cell and gene therapy #Cobra Biologics #DNA

Swedish government and industry to boost product partnerships 

Flerie Invest led a syndicate of investors in the $52 million acquisition of Cobra Biologics, Charles River Laboratories’ DNA and protein manufacturing subsidiary in Sweden. The new entity, NorthX Biologics, will take over and expand the facility, which is equipped to provide GMP-grade plasmid DNA and technical protein manufacture at commercial scale. … Read More

#News #Trending News #Trends & Analysis

#Cell and gene therapy #Drug development

From Novartis to MiroBio: CEO to lead company growth  

MiroBio has appointed Carolin Barth as CEO to lead the company through the next major stage of its growth as its lead programme, MB272, transitions into clinical development. Dr Barth’s appointment follows other recent senior appointments including Julian Hirst, formerly of Immunocore, as CFO and Lynne Murray, formerly of… Read More

#News

#Biomedicine #Cell and gene therapy #Drug development

BioIVT launches human AB serum for cell and gene therapy development 

BioIVT’s human AB serum product line is designed to supplement cell culture media and facilitate cell and gene therapy development.  Human AB serum contains many compounds that are vital for cell growth, including growth factors, vitamins, nutrients, trace elements and transport factors. As a result, human… Read More

#News

#Assays #Cell and gene therapy #Drug development #Immunology

Collaboration agreement for ImmunoBiopsy platform 

Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to deploy Savicell’s patented ImmunoBiopsy immunometabolism platform. The aim is to develop and validate diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Orgenesis in manufacturing and processing of its cell and gene therapies. New assays will be developed to enhance the potency… Read More

#Business & Investment #News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Gene therapy #Neurodegenerative disorders #Research

Gene therapy enables new treatments for neurodegenerative diseases

The University of Sheffield and the Cell and Gene Therapy Catapult have launched a gene therapy programme which could pave the way for novel treatments for neurodegenerative diseases. The research has been awarded £513,141 from LifeArc and the Motor Neurone Disease Association to test the feasibility and efficiency of a… Read More

#News

#Bioscience #Biotechnology #Cell and gene therapy #Cell and Gene Therapy Catapult #Drug development #Life sciences #Research

GSK unveils plan for one of Europe’s largest life science campuses

GSK has announced that it planning to develop its research & development site in Stevenage, UK,  into one of Europe’s largest clusters for biotechnology and early-stage life science companies. The concept has been developed in partnership with Stevenage Bioscience Catalyst (SBC), among others and would build on GSK’s existing presence,… Read More

#News

#Cell and gene therapy #Clinical trials #Diabetes

Phase II gene therapy study approved for difficult diabetic wounds

Ilya Pharma has received approval from the Swedish Medical Product Agency and Swedish Ethical Review Authority to initiate a Phase II clinical study of its ILP100 gene therapy for the treatment of difficult diabetic wounds (EudraCT 2021-000563-69). ILP100h has recently been assigned the INN name emilimogene sigulactibac by the World… Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Cell therapy

CGT Catapult to expand to Edinburgh BioQuarter

The Cell and Gene Therapy Catapult (CGT Catapult) is setting up offices and laboratories in Edinburgh, Scotland. With this expansion, CGT Catapult aims to provide additional, regionally focused support to the cell and gene therapy sector to accelerate product development, clinical trials and adoption. CGT Catapult Edinburgh is a collaboration… Read More

#News

#CAR-T #Cell and gene therapy

Takara Bio agreement with BioNTech Cell & Gene Therapies

Takara Bio has entered into a License and Supply Agreement with BioNTech Cell & Gene Therapies. Takara Bio will grant BioNTech a commercial license to use applicable patents relating to RetroNectin, and will provide BioNTech with supplies of RetroNectin. The patented technologies licensed to BioNTech are based on Takara Bio’s… Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Life sciences

Horiba joins cell and gene therapy consortium

Horiba has announced its participation in a new consortium formed to accelerate the development of process analytical technologies (PAT) in cell and gene therapy manufacturing. Horiba’s new A-TEEM Molecular Fingerprinting technology has shown great promise for fast QC/QA of complex biological systems and is a core technology being assessed for… Read More

#News

#Biologics #Cell and gene therapy #Drug development

Yposkesi launches construction of its second commercial bioproduction site

Yposkesi, a Contract Development and Manufacturing Organisation (CDMO) specialising in cell and gene therapies, has announced the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat… Read More

#News

#Bioscience #Cell and gene therapy #Gene therapy

Cell & Gene Collective to advocate for adoption of next generation medicine

The Cell & Gene Collective has been launched by companies Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis with the aim of raising awareness of the promise and challenges of the next generation of medicines – cell and gene therapies. To date, the UK has… Read More

#News

#Biotherapeutics #Cell and gene therapy #Pharmaceutical #Therapeutics

Sector trio enters R&D alliance to develop cell therapies for eye diseases

BlueRock Therapeutics, FUJIFILM Cellular Dynamics and Opsis Therapeutics have entered a strategic research joint venture focused on developing cell therapies for patients with ocular diseases. The companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases. Under this agreement, BlueRock Therapeutics will have… Read More

#News

#Bioscience #Cell and gene therapy #DNA #Gene therapy

Charles River acquisition enhances gene therapy capabilities

Charles River has signed a definitive agreement to acquire Vigene Biosciences. The purchase price is expected to be US$292.5 million, subject to customary closing adjustments. The acquisition will enhance Charles River’s gene therapy capabilities in the high-growth, value-added cell and gene therapy CDMO sector. In addition to the initial purchase… Read More

#News

#Cell and gene therapy #Drug delivery #Drug development #Drug innovation #Life sciences

RoslinCT selected as vaccines and advanced therapies training centre

RoslinCT has been confirmed as a National Training Centre, part of the Department for Business, Energy & Industrial Strategy (BEIS) sponsored Advanced Therapies Skills Training Network (ATSTN) initiative. The organisation is the second National Training Centre confirmed as part of the ATSTN initiative, which was set up to develop vaccine… Read More

#News